We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

160 hedge funds and large institutions have $1.7B invested in Agios Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 47 increasing their positions, 58 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 21

0.6% more ownership

Funds ownership: 109.02% → 109.62% (+0.6%)

0% more funds holding

Funds holding: 160 → 160 (0)

13% less capital invested

Capital invested by funds: $1.95B → $1.7B (-$245M)

13% less call options, than puts

Call options by funds: $8.77M | Put options by funds: $10.1M

19% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 58

Holders
160
Holders Change
–
Holders Change %
0%
% of All Funds
2.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
47
Reduced
58
Closed
21
Calls
$8.77M
Puts
$10.1M
Net Calls
-$1.3M
Net Calls Change
+$5.76M

Top Buyers

1
First Trust Advisors
First Trust Advisors
Illinois
+$10.5M
2
Macquarie Group
Macquarie Group
Australia
+$9.2M
3
Norges Bank
Norges Bank
Norway
+$8.87M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$8.71M
5
Axa
Axa
France
+$6.14M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$18.8M
2
BG
Bellevue Group
Switzerland
-$6.72M
3
BlackRock
BlackRock
New York
-$6.31M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$5.41M
5
UBS Group
UBS Group
Switzerland
-$4.26M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$11.5M +$294K +9,613 +2%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$10.7M -$6.94K -227 -0.1%
Morgan Stanley
28
Morgan Stanley
New York
$9.62M +$2.22M +72,595 +28%
Bank of America
29
Bank of America
North Carolina
$7.78M -$460K -15,043 -5%
Hudson Bay Capital Management
30
Hudson Bay Capital Management
Connecticut
$6.55M +$764K +25,000 +13%
Axa
31
Axa
France
$5.85M +$6.14M +200,837 New
Voloridge Investment Management
32
Voloridge Investment Management
Florida
$5.24M +$4.12M +134,850 +299%
Rafferty Asset Management
33
Rafferty Asset Management
New York
$5.18M -$12.6K -413 -0.2%
ECM
34
ExodusPoint Capital Management
New York
$4.85M +$4.74M +155,287 +1,390%
PAMS
35
Pictet Asset Management (Switzerland)
Switzerland
$3.62M +$442K +14,476 +13%
Swiss National Bank
36
Swiss National Bank
Switzerland
$3.36M -$36.7K -1,200 -1%
Connor, Clark & Lunn Investment Management (CC&L)
37
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$3.17M +$715K +23,410 +27%
BFM
38
Boothbay Fund Management
New York
$3.1M +$3.25M +106,334 New
State of New Jersey Common Pension Fund D
39
State of New Jersey Common Pension Fund D
New Jersey
$2.55M +$430K +14,081 +19%
CS
40
Credit Suisse
Switzerland
$2.41M -$26.3K -860 -1%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$2.33M – – –
Tudor Investment Corp
42
Tudor Investment Corp
Connecticut
$2.31M -$137K -4,480 -5%
Invesco
43
Invesco
Georgia
$2.23M +$1.33M +43,504 +131%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$2.2M -$193K -6,309 -8%
EVM
45
Eaton Vance Management
Massachusetts
$2.18M +$31 +1 +0%
AllianceBernstein
46
AllianceBernstein
Tennessee
$2.14M +$6.11K +200 +0.3%
Group One Trading
47
Group One Trading
Illinois
$2.11M +$2.22M +72,546 New
Principal Financial Group
48
Principal Financial Group
Iowa
$2.09M -$890K -29,126 -29%
TD Asset Management
49
TD Asset Management
Ontario, Canada
$2.06M -$494K -16,160 -19%
ACM
50
Altium Capital Management
New York
$1.93M +$2.02M +66,196 New
1
2
3 4 5

AGIO Hedge Fund Activity: Q1 2022 in Review

160 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2022, worth a combined $1.7B — down 13% from $1.95B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new AGIO positions and 21 closed out — a net gain of 2 holders — while 47 added to existing stakes and 58 trimmed.

The largest buyer was First Trust Advisors, adding an estimated $10.5M. The largest seller was Fidelity Investments, cutting an estimated $18.8M.

  • 160 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2022, unchanged from Q4 2021.
  • Funds reported $1.7B of Agios Pharmaceuticals stock for Q1 2022, down 13% quarter-over-quarter.
  • 23 funds opened new Agios Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +2 holders.
  • The largest Agios Pharmaceuticals buyer in Q1 2022 was First Trust Advisors, an estimated $10.5M added.
  • The largest Agios Pharmaceuticals seller in Q1 2022 was Fidelity Investments, an estimated $18.8M sold.

Based on aggregated 13F filings for Q1 2022.